Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

es that regulatory filings to support initiation of this clinical trial will be completed by mid-year 2007. Kosan plans to initiate a larger, international Phase 2/3 trial of alvespimycin in combination with trastuzumab in patients with HER2-positive metastatic breast cancer later in 2007.

Kosan also plans to pursue development of alvespimycin as a treatment for patients with acute myeloid leukemia (AML).

Kosan is also testing alvespimycin delivered orally in a Phase 1 dose escalation trial on both daily and every other day schedules. While dose escalation continues in this trial, early results have shown prolonged stable disease in patients with fibrosarcoma, hemangioendothelioma, melanoma and renal cell carcinoma with a favorable side effect profile.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global devel
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... YORK, Pa. , Nov. 25, 2014  Unilife ... supplier of injectable drug delivery systems, today announced that ... scheduled to present at the Piper Jaffray 26th Annual ... 8:30 a.m. EST on Tuesday, December 2, 2014. ... the Internet as a "live" listen only Webcast. To ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... UPI ) announced today that it will release financial ... at the market close on Monday, November 2, 2009. ... results on Monday, November 2, 2009 at 3:30 p.m. Central ... Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will ...
... 21 Shire plc,(LSE: SHP, NASDAQ: SHPGY ), ... Biologics License Application (BLA) with the U.S.,Food and Drug ... for Fabry disease, by the end of the year. ... filed at the,request of FDA, has been approved, and ...
Cached Medicine Technology:Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 4
(Date:11/26/2014)... NY (PRWEB) November 26, 2014 Call ... research requirements or email the details on sales(at)researchmoz(dot)us ... diabetes and drug discovery market 2014" with deep study ... is the result of high blood sugar. The global ... directly linked to the growing number of diabetics in ...
(Date:11/26/2014)... Aurora, CO (PRWEB) November 26, 2014 For ... fast, the new LES MILLS BODYPUMP™ classes at ... be just the workout they've been looking for. The 45- ... with CU Anschutz Health and Wellness Center fitness club memberships. ... muscles. The workouts are fast-paced and are aimed at fast ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Vultures have developed highly ... ingest when eating dead animals, researchers report. The ... on the faces and in the guts of 50 ... On average, the faces of the vultures had more ... in their guts, the study found. The findings ...
(Date:11/26/2014)... -- Exposure to peanut protein in household dust may ... the skin condition eczema, a new study reveals. ... States are allergic to peanuts. And severe eczema in ... allergy, the researchers noted. The new study included ... researchers examined the amount of peanut protein the children ...
Breaking Medicine News(10 mins):Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... opposite trend, latest one reflects entire U.S. population, experts ... some recent research has documented an upswing in mastectomy ... cancer, a new study comes to a different conclusion. ... decrease overall nationwide," said study author Dr. Elizabeth Habermann, ...
... ... Appeal and Wellness Benefits for Gamers , ... Los Angeles, CA (Vocus) June 15, 2010 -- Beamz Interactive , an ... of all ages and skill levels to play music, today announced a strategic partnership with ...
... the June edition of the Journal of Thoracic ... surgical outcomes of patients with non-small cell lung cancer ... cancer continues to rise; therefore, countermeasures to decrease death ... analyzing the time trends, researchers postulated that the increase ...
... This ... style and function are now standard accessories for most dog owners. The Rubit! provides a quick ... or the danger of a broken fingernail.The clip functions between the collar and an ID tags ... (PRWEB) June 15, 2010 ...
... new cancer medication sorafenib looks promising. Sorafenib is used ... to be effective against cancer stem cells in pancreatic ... Head of the Department of Molecular Oncosurgery, a group ... (Managing Director: Professor Dr. Markus W. Bchler) in cooperation ...
... reason why depression and other stress-related psychiatric disorders are ... signaling systems in animal brains, neuroscience researchers found that ... important stress hormone and less able to adapt to ... evidence for sex differences in how neurotransmitter receptors traffic ...
Cached Medicine News:Health News:Mastectomy Rates Down Overall, New Study Finds 2Health News:Mastectomy Rates Down Overall, New Study Finds 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 2Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 4Health News:Lung cancer research concludes that early diagnosis as key for improving survival 2Health News:The Rubit Dog Tag Clips Making Big Pet Store Sales, Everyday Dog Ownership Easier, Preventing Broken Fingernails. 2Health News:New combination effective against pancreatic cancer 2Health News:Higher anxiety, depression among women may have basis in cell signals 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: